Components of the microenvironment of soft tissue sarcomas. Part I

Cover Page

Cite item

Full Text

Abstract

Soft tissue sarcomas (STS) are a rare heterogeneous group of malignant neoplasms characterized by aggressive course and poor response to treatment. This determines the relevance of research aimed at studying the pathogenesis of STS. The tumor microenvironment consists of stromal, immune cells, blood, lymphatic vessels, and extracellular matrix. By now, it is known that STS is characterized by complex relationships between tumor cells and components of the microenvironment. Dynamic interactions between tumor cells and components of the microenvironment enhance adaptation to changing environmental conditions, which provides high aggressive potential of STS and resistance to antitumor therapy. Basic research aimed at investigating the role of microenvironmental components in STS carcinogenesis may serve as a key to the discovery of both new prognostic predictor biomarkers and targets for new antitumor drugs. This review article is devoted to the role and interaction of STS cells with components of the microenvironment.

About the authors

A. V. Lokhonina

Scientific Research Institute of Molecular and Cellular Medicine of the Peoples’ Friendship University of Russia; National Medical research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov, Ministry of Health of Russia; Medical Institute of the Peoples’ Friendship University of Russia

Author for correspondence.
ORCID iD: 0000-0001-8077-2307

6 Miklukho-Maklaya St., Moscow 117198

4 Akademika Oparina St., Moscow 117997

 

Russian Federation

E. D. Jumaniyazova

Scientific Research Institute of Molecular and Cellular Medicine of the Peoples’ Friendship University of Russia; Medical Institute of the Peoples’ Friendship University of Russia

Email: enar2017@yandex.ru
ORCID iD: 0000-0002-8226-0433

6 Miklukho-Maklaya St., Moscow 117198

Russian Federation

D. Sh. Dzhalilova

Scientific Research Institute of Molecular and Cellular Medicine of the Peoples’ Friendship University of Russia; Research Institute of Human Morphology of the B.V. Petrovsky Russian Scientific Center of Surgery

ORCID iD: 0000-0002-1337-7160

6 Miklukho-Maklaya St., Moscow 117198

Russian Federation

A. M. Kosyreva

Scientific Research Institute of Molecular and Cellular Medicine of the Peoples’ Friendship University of Russia; Medical Institute of the Peoples’ Friendship University of Russia; Research Institute of Human Morphology of the B.V. Petrovsky Russian Scientific Center of Surgery

ORCID iD: 0000-0002-6182-1799

6 Miklukho-Maklaya St., Moscow 117198

3 Tsyurupy St., Moscow 117418

Russian Federation

G. G. Kazaryan

Medical Institute of the Peoples’ Friendship University of Russia

ORCID iD: 0000-0002-3532-983X

6 Miklukho-Maklaya St., Moscow 117198

Russian Federation

T. Kh. Fatkhudinov

Scientific Research Institute of Molecular and Cellular Medicine of the Peoples’ Friendship University of Russia; Medical Institute of the Peoples’ Friendship University of Russia; Research Institute of Human Morphology of the B.V. Petrovsky Russian Scientific Center of Surgery

ORCID iD: 0000-0002-6498-5764

6 Miklukho-Maklaya St., Moscow 117198

3 Tsyurupy St., Moscow 117418

Russian Federation

References

  1. Blay J.Y. Evolution in soft tissue sarcoma. Future Oncol 2017;13(1s):1–2. doi: 10.2217/fon-2016-0497
  2. Almas T., Khan M.K., Murad M.F. et al. Clinical and pathological characteristics of soft tissue sarcomas: a retrospective study from a developing country. Cureus 2020;12(8):e9913. doi: 10.7759/cureus.9913
  3. Ramu E.M., Houdek M.T., Isaac C.E. et al. Management of soft-tissue sarcomas; treatment strategies, staging, and outcomes. SICOT J 2017;3:20. doi: 10.1051/sicotj/2017010
  4. Gerrand C.H., Bell R.S., Wunder J.S. et al. The influence of anatomic location on outcome in patients with soft tissue sarcoma of the extremity. Cancer 2003;97(2):485–92. doi: 10.1002/cncr.11076
  5. Chintamani. Soft tissue sarcomas-the pitfalls in diagnosis and management. Indian J Surg Oncol 2011;2(4):261–4. doi: 10.1007/s13193-012-0141-7
  6. Hatina J., Kripnerova M., Houfkova K. et al. Sarcoma stem cell heterogeneity. Adv Exp Med Biol 2019;1123:95–118. doi: 10.1007/978-3-030-11096-3_7
  7. Zeng D., Li M., Zhou R., Zhang J. et al. Tumor microenvironment characterization in gastric cancer identifies prognostic and immunotherapeutically relevant gene signatures. Cancer Immunol Res 2019;7(5):737–50. doi: 10.1158/2326-6066.CIR-18-0436
  8. Deng J., Zeng W., Kong W. et al. The study of sarcoma microenvironment heterogeneity associated with prognosis based on an immunogenomic landscape analysis. Front Bioeng Biotechnol 2020;8:1003. doi: 10.3389/fbioe.2020.01003
  9. Wang Q., Shao X., Zhang Y. et al. Role of tumor microenvironment in cancer progression and therapeutic strategy. Cancer Med 2023;12(10):11149–65. doi: 10.1002/cam4.5698
  10. Tessaro F.H., Ko E.Y., De Simone M. et al. Single-cell RNA-seq of a soft-tissue sarcoma model reveals the critical role of tumorexpressed MIF in shaping macrophage heterogeneity. Cell Rep 2022;39(12):110977. doi: 10.1016/j.celrep.2022.110977
  11. Petitprez F., de Reyniès A., Keung E.Z. et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature 2020;577(7791):556–60. doi: 10.1038/s41586-019-1906-8
  12. Stahl D., Gentles A.J., Thiele R. et al. Prognostic profiling of the immune cell microenvironment in Ewing’s Sarcoma Family of Tumors. Oncoimmunology 2019;8(12):e1674113. doi: 10.1080/2162402X.2019.1674113
  13. Hu C., Chen B., Huang Z. et al. Comprehensive profiling of immunerelated genes in soft tissue sarcoma patients. J Translat Med 2020;18:1–18. doi: 10.1186/s12967-020-02512-8
  14. Gu H.Y., Lin L.L., Zhang C. et al. The potential of five immune-related prognostic genes to predict survival and response to immune checkpoint inhibitors for soft tissue sarcomas based on multi-omic study. Front Oncol 2020;10:1317. doi: 10.3389/fonc.2020.01317
  15. Tsagozis P., Augsten M., Zhang Y. et al. An immunosuppressive macrophage profile attenuates the prognostic impact of CD20-positive B cells in human soft tissue sarcoma. Cancer Immunol Immunother 2019;68(6):927–36. doi: 10.1007/s00262-019-02322-y
  16. Dufresne A., Lesluyes T., Ménétrier-Caux C. et al. Specific immune landscapes and immune checkpoint expressions in histotypes and molecular subtypes of sarcoma. Oncoimmunology 2020;9(1):1792036. doi: 10.1080/2162402X.2020.1792036
  17. Zhu N., Hou J. Assessing immune infiltration and the tumor microenvironment for the diagnosis and prognosis of sarcoma. Cancer Cell Int 2020;20(1):1–11. doi: 10.1186/s12935-020-01672-3
  18. Zhou J., Tang Z., Gao S. et al. Tumor-associated macrophages: recent insights and therapies. Front Oncol 2020;10:188. doi: 10.3389/fonc.2020.00188
  19. Mantovani A., Marchesi F., Malesci A. et al. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol 2017;14(7):399–416. doi: 10.1038/nrclinonc.2016.217
  20. Najafi M., Hashemi Goradel N., Farhood B. et al. Macrophage polarity in cancer: a review. J Cell Biochem 2019;120(3):2756–65. doi: 10.1002/jcb.27646
  21. Nyström H., Jönsson M., Nilbert M. et al. Immune-cell infiltration in high-grade soft tissue sarcomas; prognostic implications of tumorassociated macrophages and B-cells. Acta Oncol 2023;62(1):33–9. doi: 10.1080/0284186X.2023.2172688
  22. Seong G., D’Angelo S.P. New therapeutics for soft tissue sarcomas: overview of current immunotherapy and future directions of soft tissue sarcomas. Front Oncol 2023;13:1150765. doi: 10.3389/fonc.2023.1150765
  23. Cheng S., Li Z., Gao R., Xing B. et al. A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells. Cell 2021;184(3):792–809. doi: 10.1016/j.cell.2021.01.010
  24. El-Kenawi A., Dominguez-Viqueira W., Liu M. et al. Macrophagederived cholesterol contributes to therapeutic resistance in prostate cancer. Cancer Res 2021;81(21):5477–90. doi: 10.1158/0008-5472.CAN-20-4028
  25. Cassetta L., Pollard J.W. Targeting macrophages: therapeutic approaches in cancer. Nat Rev Drug Discov 2018;17(12):887–904. doi: 10.1038/nrd.2018.169
  26. Fujiwara T., Yakoub M.A., Chandler A. et al. CSF1/CSF1R signaling inhibitor pexidartinib (PLX3397) reprograms tumor-associated macrophages and stimulates T-cell infiltration in the sarcoma microenvironment. Mol Cancer Ther 2021;20(8):1388–99. doi: 10.1158/1535-7163.MCT-20-0591
  27. Lee C.H., Espinosa I., Vrijaldenhoven S. et al. Prognostic significance of macrophage infiltration in leiomyosarcomas. Clin Cancer Res 2008;14(5):1423–30. doi: 10.1158/1078-0432.CCR-07-1712
  28. Nabeshima A., Matsumoto Y., Fukushi J. et al.Tumour-associated macrophages correlate with poor prognosis in myxoid liposarcoma and promote cell motility and invasion via the HB-EGF-EGFR-PI3K/ Akt pathways. B J Cancer 2015;112(3):547–55. doi: 10.1038/bjc.2014.637
  29. Oike N., Kawashima H., Ogose A. et al. Prognostic impact of the tumor immune microenvironment in synovial sarcoma. Cancer Sci 2018;109(10):3043–54. doi: 10.1111/cas.13769
  30. Kather J.N., Hörner C., Weis C.A. et al. CD163+ immune cell infiltrates and presence of CD54+ microvessels are prognostic markers for patients with embryonal rhabdomyosarcoma. Sci Rep 2019;9(1):9211. doi: 10.1038/s41598-019-45551-y
  31. Minopoli M., Sarno S., Cannella L. et al. Crosstalk between macrophages and myxoid liposarcoma cells increases spreading and invasiveness of tumor cells. Cancers 2021;13(13):3298. doi: 10.3390/cancers13133298
  32. Qayoom H., Sofi S., Mir M.A. Targeting tumor microenvironment using tumor-infiltrating lymphocytes as therapeutics against tumorigenesis. Immunol Res 2023;71(4):588–99. doi: 10.1007/s12026-023-09376-2
  33. Badalamenti G., Fanale D., Incorvaia L. et al. Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone? Cell Immunol 2019;343:103753. doi: 10.1016/j.cellimm.2018.01.013
  34. Smolle M.A., Herbsthofer L., Granegger B. et al. T-regulatory cells predict clinical outcome in soft tissue sarcoma patients: A clinicopathological study. Br J Cancer 2021;25(5):717–24. doi: 10.1038/s41416-021-01456-0
  35. Hemminger J.A., Iwenofu O.H. NY-ESO-1 is a sensitive and specific immunohistochemical marker for myxoid and round cell liposarcomas among related mesenchymal myxoid neoplasms. Mod Pathol 2013;26(9):1204–10. doi: 10.1038/modpathol.2013.65
  36. Sorbye S.W., Kilvaer T., Valkov A. et al. Prognostic impact of lymphocytes in soft tissue sarcomas. PLoS One 2011;6(1):e14611. doi: 10.1371/journal.pone.0014611
  37. Pollack S.M., He Q., Yearley J.H. et al. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed deathligand 1 expression in patients with soft tissue sarcomas. Cancer 2017;123(17):3291–304. doi: 10.1002/cncr.30726
  38. Nakajima K., Raz A. T-cell infiltration profile in musculoskeletal tumors. J Orthop Res 2021;39(3):536–42. doi: 10.1002/jor.24890
  39. Fujii H., Arakawa A., Utsumi D. et al. CD8+ tumor-infiltrating lymphocytes at primary sites as a possible prognostic factor of cutaneous angiosarcoma. Int Journal Cancer 2014;134(10):2393–402. doi: 10.1002/ijc.28581
  40. Van Erp A.E., Versleijen-Jonkers Y.M., Hillebrandt-Roeffen M.H. et al. Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8+ lymphocytes in primary sarcomas is subtype dependent. Oncotarget 2017;8(41):71371. doi: 10.18632/oncotarget.19071
  41. Nowicki T.S., Akiyama R., Huang R.R. et al. Infiltration of CD8 T cells and expression of PD-1 and PD-L1 in synovial sarcoma. Cancer Immunol Res 2017;5(2):118–26. doi: 10.1158/2326-6066.CIR-16-0148
  42. Liu Y., Cao X. Immunosuppressive cells in tumor immune escape and metastasis. J Mol Med 2016;94(5):509–22. doi: 10.1007/s00109-015-1376-x
  43. D’Angelo S.P., Shoushtari A.N., Agaram N.P. et al. Prevalence of tumorinfiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Human Pathol 2015;46(3):357–65. doi: 10.1016/j.humpath.2014.11.001
  44. Li L.J., Shi Y.C., Luo M.X. et al. Effects of moxibustion on Treg cells in sarcoma microenvironment. Journal of Integrative Medicine 2021;19(3):251–7. doi: 10.1016/j.joim.2021.02.001
  45. Que Y., Xiao W., Guan Y.X. et al. PD-L1 expression is associated with FOXP3+ regulatory T-cell infiltration of soft tissue sarcoma and poor patient prognosis. J Cancer 2017;8(11):2018. doi: 10.7150/jca.18683
  46. Keung E.Z., Burgess M., Salazar R. et al. Correlative analyses of the SARC028 trial reveal an association between sarcoma-associated immune infiltrate and response to pembrolizumab. Clin Cancer Res 2020;26(6):1258–66. doi: 10.1158/1078-0432.CCR-19-1824
  47. Judge S.J., Darrow M.A., Thorpe S.W. et al. Analysis of tumorinfiltrating NK and T cells highlights IL-15 stimulation and TIGIT blockade as a combination immunotherapy strategy for soft tissue sarcomas. J Immunother Cancer 2020;8(2):e001355. doi: 10.1136/jitc-2020-001355
  48. Sharonov G.V., Serebrovskaya E.O., Yuzhakova D.V. et al. B cells, plasma cells and antibody repertoires in the tumour microenvironment. Nature Rev Immunol 2020;20(5):294–307. doi: 10.1038/s41577-019-0257-x
  49. Premkumar K., Shankar B.S. TGF-βR inhibitor SB431542 restores immune suppression induced by regulatory B–T cell axis and decreases tumour burden in murine fibrosarcoma. Cancer Immunol Immunother 2021;70(1):153–68. doi: 10.1007/s00262-020-02666-w
  50. Tseng W.W., Malu S., Zhang M. et al. Analysis of the intratumoral adaptive immune response in well differentiated and dedifferentiated retroperitoneal liposarcoma. Sarcoma 2015;2015:547460. doi: 10.1155/2015/547460
  51. Sorbye S.W., Kilvaer T.K., Valkov A. et al. Prognostic impact of CD57, CD68, M-CSF, CSF-1R, Ki67 and TGF-beta in soft tissue sarcomas. BMC Clin Pathol 2012;12(1):1–11. doi: 10.1371/journal.pone.0014611
  52. Sorbye S.W., Kilvaer T.K., Valkov A. et al. Prognostic impact of peritumoral lymphocyte infiltration in soft tissue sarcomas. BMC Clin Pathol 2012;12(1):1–10. doi: 10.1186/1472-6890-12-5
  53. Lazar A.J., McLellan M.D., Bailey M.H. et al. Comprehensive and integrated genomic characterization of adult soft tissue sarcomas. Cell 2017;171(4):950–65. doi: 10.1016/j.cell.2017.10.014
  54. Sousa L.M., Almeida J.S., Fortes-Andrade T. et al. Tumor and peripheral immune status in soft tissue sarcoma: implications for immunotherapy. Cancers 2021;13(15):3885. doi: 10.3390/cancers13153885
  55. Ponzetta A., Carriero R., Carnevale S. et al. Neutrophils driving unconventional T cells mediate resistance against murine sarcomas and selected human tumors. Cell 2019;178(2):346–60. doi: 10.1016/j.cell.2019.05.047
  56. Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer 2016;16(9):582–98. doi: 10.1038/nrc.2016.73
  57. Joshi R.S., Kanugula S.S., Sudhir S. et al. The role of cancer-associated fibroblasts in tumor progression. Cancers 2021;13(6):1399. doi: 10.3390/cancers13061399
  58. LeBleu V.S., Kalluri R. A peek into cancer-associated fibroblasts: origins, functions and translational impact. Dis Model Mech 2018;11(4):dmm029447. doi: 10.1242/dmm.029447
  59. Erdogan B., Webb D.J. Cancer-associated fibroblasts modulate growth factor signaling and extracellular matrix remodeling to regulate tumor metastasis. Biochem Soc Trans 2017;45(1):229–36. doi: 10.1042/BST20160387
  60. Kudo A., Yoshimoto S., Yoshida H. et al. Biological features of canine cancer-associated fibroblasts and their influence on cancer cell invasion. J Vet Med Sci 2022;84(6):784–91. doi: 10.1292/jvms.22-0041
  61. Feng C., Kou L., Yin P. et al. Excessive activation of IL­33/ST2 in cancer­associated fibroblasts promotes invasion and metastasis in ovarian cancer. Oncol Lett 2022;23(5):1–12. doi: 10.3892/ol.2022.13278
  62. Komohara Y., Takeya M. CAFs and TAMs: maestros of the tumour microenvironment. J Pathol 2017;241(3):313–5. doi: 10.1002/path.4824
  63. Harati K., Daigeler A., Hirsch T. et al. Tumor-associated fibroblasts promote the proliferation and decrease the doxorubicin sensitivity of liposarcoma cells. Int J Mol Med 2016;37(6):1535–41. doi: 10.3892/ijmm.2016.2556
  64. Wright K., Ly T., Kriet M. et al. Cancer-associated fibroblasts: master tumor microenvironment modifiers. Cancers 2023;1(6):1899. doi: 10.3390/cancers15061899
  65. Huang H., Wang Z., Zhang Y. et al Mesothelial cell-derived antigenpresenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer. Cancer Cell 2022;40(6):656–73. doi: 10.1016/j.ccell.2022.04.011
  66. Mao X., Xu J., Wang W., Liang C. et al. Crosstalk between cancerassociated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer 2021;20(1):1–30. doi: 10.1186/s12943-021-01428-1
  67. Manzur M., Hamzah J., Ganss R. Modulation of the “blood-tumor” barrier improves immunotherapy. Cell Cycle 2008;7(16):2452–5. doi: 10.4161/cc.7.16.6451
  68. Lee C.T., Mace T., Repasky E.A. Hypoxia-driven immunosuppression: a new reason to use thermal therapy in the treatment of cancer? Int J Hyperthermia 2010;26(3):232–46. doi: 10.3109/02656731003601745
  69. Nordsmark M., Alsner J., Keller J. et al. Hypoxia in human soft tissue sarcomas: adverse impact on survival and no association with p53 mutations. Br J Cancer 2001;84(8):1070–5. doi: 10.1054/bjoc.2001.1728
  70. Pouysségur J., Dayan F., Mazure N.M. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006;441(7092): 437–43. doi: 10.1038/nature04871
  71. Aggerholm-Pedersen N., Sørensen B.S., Overgaard J. et al. A prognostic profile of hypoxia-induced genes for localised high-grade soft tissue sarcoma. Br J Cancer 2016;115(9):1096–104. doi: 10.1038/bjc.2016.310
  72. Nyström H., Jönsson M., Werner-Hartman L. et al. Hypoxia-inducible factor 1α predicts recurrence in high-grade soft tissue sarcoma of extremities and trunk wall. J Clin Pathol 2017;70(10):879–85. doi: 10.1136/jclinpath-2016-204149
  73. Pakos E.E., Goussia A.C., Tsekeris P.G. et al. Expression of vascular endothelial growth factor and its receptor, KDR/Flk-1, in soft tissue sarcomas. Anticancer Res 2005;25(5):3591–6.
  74. Yudoh K., Kanamori M., Ohmori K. et al. Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas. Br J Cancer 2001;84(12):1610–5. doi: 10.1054/bjoc.2001.1837
  75. Hayes A.J., Mostyn-Jones A., Koban M.U. et al. Serum vascular endothelial growth factor as a tumour marker in soft tissue sarcoma. Br J Surg 2004;91(2):242–7. doi: 10.1002/bjs.4398
  76. Tomlinson J., Barsky S.H., Nelson S. et al. Different patterns of angiogenesis in sarcomas and carcinomas. Clin Cancer Res 1999;5(11):3516–22.
  77. Tammela T., Zarkada G., Wallgard E. et al. VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 2008;454(7204):656–60. doi: 10.1038/nature07083
  78. Yoon S.S., Segal N.H., Park P.J. et al. Angiogenic profile of soft tissue sarcomas based on analysis of circulating factors and microarray gene expression. J Surg Res 2006;135(2):282–90. doi: 10.1016/j.jss.2006.01.023
  79. Kilvaer T.K., Valkov A., Sorbye S.W. Fibroblast growth factor 2 orchestrates angiogenic networking in non-GIST STS patients. J Transl Med 2011;9:104. doi: 10.1186/1479-5876-9-104
  80. Rocchi L., Caraffi S., Perris R. et al. The angiogenic asset of soft tissue sarcomas: a new tool to discover new therapeutic targets. Biosci Rep 2014;34(6):e00147. doi: 10.1042/BSR20140075

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Lokhonina A.V., Jumaniyazova E.D., Dzhalilova D.S., Kosyreva A.M., Kazaryan G.G., Fatkhudinov T.K.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-66671 от  09.11.2009.